Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months ending September 2020 and full year Ending March 31, 2021. For the six months, the company expects net sales to be ¥41,000 million, operating profit to be ¥10,900 million, ordinary profit to be ¥11,100 million, profit attributable to owners of the parent to be ¥7,900 million or ¥203.00 per share. For the full year, the company expects net sales to be ¥82,900 million, operating profit to be ¥20,800 million, ordinary profit to be ¥21,200 million, profit attributable to owners of the parent to be ¥15,000 million or ¥385.43 per share.